CHINA PHARMA HOLDINGS, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$796.89 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-04-01
- CHINA PHARMA HOLDINGS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$796.89K.
- CHINA PHARMA HOLDINGS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$1.18M.
- CHINA PHARMA HOLDINGS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$769.70K.
- CHINA PHARMA HOLDINGS, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was -$973.72K.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$796.89K 10-K · filed 2026-04-01 |
| 2024-12-31 | -$1.18M 10-K · filed 2026-04-01 |
| 2023-12-31 | -$769.70K 10-K · filed 2025-03-31 |
| 2022-12-31 | -$973.72K 10-K · filed 2024-04-01 |
| 2021-12-31 | -$849.87K 10-K · filed 2023-03-30 |
| 2020-12-31 | -$716.69K 10-K · filed 2022-03-30 |
| 2019-12-31 | -$5.18M 10-K · filed 2021-03-26 |
| 2018-12-31 | -$2.72M 10-K · filed 2020-03-30 |
| 2017-12-31 | -$4.79M 10-K · filed 2019-03-28 |
| 2016-12-31 | -$2.22M 10-K · filed 2018-04-02 |
| 2015-12-31 | -$3.83M 10-K · filed 2017-03-31 |
| 2014-12-31 | -$9.87M 10-K · filed 2016-03-30 |
| 2013-12-31 | -$4.74M 10-K · filed 2015-12-28 |
| 2012-12-31 | $983.92K 10-K · filed 2013-03-14 |
| 2011-12-31 | $3.44M 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |